Hilal A. Lashuel logo  logo

Hilal A. Lashuel

Research Development and Innovation Advisor to the Chairperson of Qatar Foundation and Executive Director of RDI at the Chairperson’s Office, Qatar Foundation, (Qatar)


Prof. Hilal Lashuel is the Research Development and Innovation Advisor to the Chairperson of Qatar Foundation and Executive Director of RDI at the Chairperson’s Office. He is also a Professor Emeritus at EPFL (Switzerland) and Founder and Chief Scientific Officer of ND BioSciences SA. His research focuses on developing novel disease models and mechanism-based therapies and diagnostics for early intervention and monitoring disease progression. Research in the Lashuel Laboratory focuses on applying integrated chemical, biophysical, and molecular/cellular biology approaches to uncover the molecular and structural mechanisms that drive protein misfolding, aggregation, pathology formation, and spreading in the brain. By elucidating not only the earliest triggers of pathology formation and neurodegeneration but also the key processes that drive disease progression, the lab aims to lay the foundation for developing mechanism-based, disease modifying therapies and next-generation diagnostic tools. His work spans several neurodegenerative disorders, including Parkinson’s disease (PD), Multiple System Atrophy (MSA), Dementia with Lewy Bodies (DLB), and Alzheimer’s disease, conditions that share common pathological features such as protein misfolding, aggregation, and, in many cases, the accumulation and spread of a-synuclein pathology.

Prof. Lashuel’s scientific contributions include: 1) 240 publications in peer-reviewed journals; 2) Nine patents on novel strategies for detecting and preventing protein aggregation, treating autoimmune and inflammatory diseases; 3) Over 260 invited lectures; and 3) More than 34,000 citations with an hindex of 97. He has received numerous awards and honors, including the Takreem Foundation’s Scientific & Technological Achievement Award, the Kuwait Prize in Fundamental Sciences (Biological Sciences), the H. Martin Friedman Distinguished Lecture at Brooklyn College (CUNY), the EPFL-Section of Life Sciences and Technologies Ambition Award, ERC starting and proof of concept grants, and the Human Frontiers Science Young Investigator Award. In 2012, he was named a Young Global Leader by the World Economic Forum and was featured by the Swiss business magazine LI Hebdo among the “100 outstanding personalities” in the French-speaking part of Switzerland (Forum des 100).

Publications: https://pubmed.ncbi.nlm.nih.gov/?term=lashuel&sort=date
Lashuel Lab website: https:/_lwww.epfl.ch/labs/lashuel-lab/publications/
Pubmed: https://pubmed.ncbi.nlm.nih.gov/?term=lashuel&sort=date
Google Scholar: https://scholar.google.com/citations?user=tDdAP4EAAAAJ&hl=en&oi=ao

Hilal A. Lashuel logo

Hilal A. Lashuel

Research Development and Innovation Advisor to the Chairperson of Qatar Foundation and Executive Director of RDI at the Chairperson’s Office, Qatar Foundation, (Qatar)


 logo

Prof. Hilal Lashuel is the Research Development and Innovation Advisor to the Chairperson of Qatar Foundation and Executive Director of RDI at the Chairperson’s Office. He is also a Professor Emeritus at EPFL (Switzerland) and Founder and Chief Scientific Officer of ND BioSciences SA. His research focuses on developing novel disease models and mechanism-based therapies and diagnostics for early intervention and monitoring disease progression. Research in the Lashuel Laboratory focuses on applying integrated chemical, biophysical, and molecular/cellular biology approaches to uncover the molecular and structural mechanisms that drive protein misfolding, aggregation, pathology formation, and spreading in the brain. By elucidating not only the earliest triggers of pathology formation and neurodegeneration but also the key processes that drive disease progression, the lab aims to lay the foundation for developing mechanism-based, disease modifying therapies and next-generation diagnostic tools. His work spans several neurodegenerative disorders, including Parkinson’s disease (PD), Multiple System Atrophy (MSA), Dementia with Lewy Bodies (DLB), and Alzheimer’s disease, conditions that share common pathological features such as protein misfolding, aggregation, and, in many cases, the accumulation and spread of a-synuclein pathology.

Prof. Lashuel’s scientific contributions include: 1) 240 publications in peer-reviewed journals; 2) Nine patents on novel strategies for detecting and preventing protein aggregation, treating autoimmune and inflammatory diseases; 3) Over 260 invited lectures; and 3) More than 34,000 citations with an hindex of 97. He has received numerous awards and honors, including the Takreem Foundation’s Scientific & Technological Achievement Award, the Kuwait Prize in Fundamental Sciences (Biological Sciences), the H. Martin Friedman Distinguished Lecture at Brooklyn College (CUNY), the EPFL-Section of Life Sciences and Technologies Ambition Award, ERC starting and proof of concept grants, and the Human Frontiers Science Young Investigator Award. In 2012, he was named a Young Global Leader by the World Economic Forum and was featured by the Swiss business magazine LI Hebdo among the “100 outstanding personalities” in the French-speaking part of Switzerland (Forum des 100).

Publications: https://pubmed.ncbi.nlm.nih.gov/?term=lashuel&sort=date
Lashuel Lab website: https:/_lwww.epfl.ch/labs/lashuel-lab/publications/
Pubmed: https://pubmed.ncbi.nlm.nih.gov/?term=lashuel&sort=date
Google Scholar: https://scholar.google.com/citations?user=tDdAP4EAAAAJ&hl=en&oi=ao


Why WIN